By: Syed Zainulabdin RizviOld Book. 3D Model of Men by: Syed Zainulabdin RizviMen. 3D Model of Modern Room by: Syed Zainulabdin RizviModern Room. Join a vivid community of 3D artists from around the world! Download free 3d models, engage with the community, share your work.

Title: Assistant Professor Office Information: Office: 4029 Thurston-Bowles; 919-966-4934 Education: B.A. - Natural Sciences-Biology, Johns Hopkins University M.S.

- Tumor Biology, Georgetown University Ph.D. - Engineering Sciences, Dartmouth College Postdoctoral - Department of Medicine, Brigham and Women's Hospital, Harvard Medical School; Department of Dermatology, Wellman Center for Photomedicine, Massachusetts General Hospital, Harvard Medical School Email: imran.rizvi@unc.edu Research and Publications: Dr. Rizvi's expertise is in imaging and therapeutic applications of light, bioengineered 3D models and animal models for cancer, and targeted drug delivery for inhibition of molecular survival pathways in tumors. His K99/R00 (NCI) develops photodynamic therapy (PDT)-based combinations against molecular pathways that are altered by fluidic stress in ovarian cancer. He was also co-PI on an Innovation Award with Bristol-Myers Squibb to develop optical techniques in immuno-oncology for light-based modulation of immune response. He has co-authored 40 peer-reviewed publications and 5 book chapters with a focus on PDT, biomedical optics, and molecular targeting in cancer. Rizvi moved to Chapel Hill from Boston where he was an Assistant Professor of Dermatology (tenure-track) at Harvard Medical School (HMS), and an Assistant Biomedical Engineer at the Wellman Center for Photomedicine (WCP), Massachusetts General Hospital (MGH).

He holds a Ph.D. In Engineering Sciences from the Thayer School of Engineering at Dartmouth College, an M.S. In Tumor Biology from the Lombardi Comprehensive Cancer Center at Georgetown University, and a B.A. From Johns Hopkins University. Rizvi is a Council Member of the of the American Society for Photobiology (ASP), Chair of the ASP Awards Committee, and Secretary of the Executive Committee of the Pan-American Photodynamic Association. He serves on several organizing committees and Scientific Advisory Boards including the Program Committee for SPIE Photonics West (BIOS Conference B0110), and the World Congress of the International Photodynamic Association. He has been the beneficiary of exceptional mentorship throughout his career primarily by Dr.

Tayyaba Hasan (WCP, MGH, HMS). Additional key mentors include Dr. Utkan Demirci (post-doc co-advisor, currently at Stanford University), Dr. Brian Pogue (Ph.D. Co-advisor, Dartmouth College), and Dr. David Kessel (Wayne State University). Selected Publications Links.

Spravka tematicheskogo kontrolya po obzh v dou. Comment5, kak_proiti_zadanie_strelok_v_dying_light, iwla, universal_termsrv. Tweet with a location. You can add location information to your Tweets, such as your city or precise location, from the web and via third-party applications. Total 1324772 links on 19 Feb 19. This is a list of titles, by which our users could found a posts. Each title it is a separate search query. You can to extend the Index, if you a.

Metastatic ovarian cancer (OvCa) frequently recurs due to chemoresistance, highlighting the need for nonoverlapping combination therapies that mechanistically synergize to eradicate residual disease. Photodynamic therapy (PDT), a photochemistry-based cytotoxic modality, sensitizes ovarian tumors to platinum agents and biologics and has shown clinical promise against ovarian carcinomatosis.

We introduce a three-dimensional (3D) model representing adherent ovarian micrometastases and high-throughput quantitative imaging methods to rapidly screen the order-dependent effects of combining benzoporphyrin-derivative (BPD) monoacid A-based PDT with low-dose carboplatin. 3D ovarian micronodules grown on Matrigel were subjected to BPD-PDT either before or after carboplatin treatment.

We developed custom fluorescence image analysis routines to quantify residual tumor volume and viability. Carboplatin alone did not eradicate ovarian micrometastases at a dose of 400 mg/m2, leaving surviving cores that were nonsensitive or impermeable to chemotherapy. BPD-PDT (1.25 μmol/LJ/cm2) created punctate cytotoxic regions within tumors and disrupted micronodular structure. Treatment with BPD-PDT prior to low-dose carboplatin (40 mg/m2) produced a significant synergistic reduction [P.

Biological characterization of a 3D model for micrometastatic OvCa. A, OVCAR5 cells overlaid on GFR-Matrigel™ formed 3D ovarian micronodules representing adherent micrometastatic disease with B, punctate E-cadherin expression, and C, fibronectin (red) expression (blue: DAPI), markers for poor prognosis. D, mean diameter increased from 34.3μm (±2.6μm) 3 days post-plating ( n = 9) to 108.9μm (± 13.0μm) at day 10 ( n = 9) and 131.9μm (±25.3μm) at day 17 ( n = 3) (E).

Scale bars: (B) and (C), 20μm; (D) 150μm. Monolayer cultures significantly overestimate carboplatin and BPD-PDT efficacy compared to cells in 3D.

A, fractional viability of OVCAR5 cells in monolayer (striped) following carboplatin treatment (40 mg/m 2) was 0.30 (± 0.082) ( n = 10), as compared to 0.90 (± 0.057) in 3D (solid), ( n = 6) ( p. Differential patterns of cytotoxic response in carboplatin and BPD-PDT treated 3D micronodules. A, left, a representative micronodule treated with 400 mg/m 2 carboplatin showing cell death (ethidium bromide) on the periphery of a viable (calcein) tumor core, with A, right, distinct and minimally overlapping fluorescence intensity profiles.